MedTrace Logo

Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access

NCT03524846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2018-05-15

No results posted yet for this study

Summary

To investigate the effect of ascorbic acid on angiographic restenosis after percutaneous transluminal angioplasty (PTA) for dysfunctional dialysis vascular access.

Conditions

  • Hemodialysis Access Failure

Interventions

DRUG

Ascorbic Acid 300 MG

Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.

DRUG

Ascorbic Acid 600 MG

Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.

DRUG

Normal saline

Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.

Sponsors & Collaborators

  • National Taiwan University Hospital Hsin-Chu Branch

    lead OTHER

Principal Investigators

  • Chih-Cheng Wu, M.D. · Associate professor of Medicine, National Taiwan University, College of Medicine, Taipei, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03524846 on ClinicalTrials.gov